Autolus Therapeutics Plc · NASDAQ:AUTL
Autolus Therapeutics — Q4 2024 Earnings Presentation
18 slides from Autolus Therapeutics's earnings presentation, Mar 20, 2025
Slide 1: Q4 2024 Financial Results and Business Updates
Q4 2024 Financial Results and Business Updates 20 March 2025 For Investor communication only. Not for use in product promotion. Not for further distribution. Autolus.com
Slide 2: Disclaimer
Disclaimer These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,”
Slide 3: Agenda
Agenda • Welcome and Introduction: Amanda Cray, ED, Investor Relations & External Communications • Operational Highlights: Dr. Christian Itin, CEO • Financial Results: Rob Dolski, CFO • Upcoming Milestones and Conclusion: Dr. Christian Itin, CEO • Q&A: Dr. Christian Itin and Rob Dolski 3
Slide 4: 2025 Key Objectives
2025 Key Objectives Execution in 2024 set us up to achieve objectives Execute • Execute on successful commercial launch of AUCATZYL® both in the Launch U.S. and expanding into new markets • Establish the next wave of investments to expand the obe-cel Drive opportunity, advance our clinical pipeline
Slide 5: Autolus executed to plan in 2024
Autolus executed to plan in 2024 Focused on commercial launch and pipeline opportunities in 2025 • AUCATZYL approved by the FDA for the treatment of adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia on November 8, 2024 ($30m milestone from Blackstone) • AUCATZYL added t
Slide 6: FELIX trial published in New England Journal of Medicine
FELIX trial published in New England Journal of Medicine1 Favourable response rate and tolerability, despite challenging patient population High overall response rate with deep molecular responses Excellent tolerability profile • Durable responses, particularly in patients with a low-to- • Very low
Slide 7: FELIX trial: Tumor burden impact on event-free survival in adult ALL
FELIX trial: Tumor burden impact on event-free survival in adult ALL Survival outcomes show potential of long-term plateau with 12-month EFS rates 49.5% • In all patients, the median EFS was 11.9 months • Lower disease burden at lymphodepletion was associated with better outcomes 1. Roddie C, et al
Slide 8: FELIX trial: Tumor burden impact on overall survival in adult ALL
FELIX trial: Tumor burden impact on overall survival in adult ALL Estimated 6- and 12-month overall survival rates were 80.3% and 61.1%, respectively • In all patients, the median OS was 15.6 months • Lower disease burden at lymphodepletion was associated with better outcomes 1. Roddie C, et al "Obe
Slide 9: Early Momentum in the AUCATZYL Launch
Early Momentum in the AUCATZYL® Launch 33 Treatment Centers Authorized as of 3/19/25 Patient Access is on Track >85% of total U.S. medical lives covered • 30 centers covering 60% of target population completed • Anticipated payor mix: approximately 60% ahead of plan commercial and 40% government/o
Slide 10: The Nucleus: Manufacturing facility supports commercial execution
Developing Next Generation Programmed T Cell Therapies The Nucleus: Manufacturing facility supports commercial execution State of the art design and in-house operations established – groundbreaking to complete validation in 2 years Design Build Operations • Designed for 2,000+ batches per year • Tim
Slide 11: Expanding the obe-cel opportunity
Expanding the obe-cel opportunity Deep value program with potentially broad applicability
Slide 12: Growth drivers for obe-cel
Growth drivers for obe-cel Updates to be provided at R&D event in New York, April 23, 2025 • Phase 1 dose confirmation study (CARLYSLE) in SLE ongoing • All six patients dosed Autoimmune • Initial data to be presented at R&D event on April 23, 2025 • H2 2025 for presentation of full data with longer
Slide 13: The obe-cel product family and franchise opportunity
The obe-cel product family and franchise opportunity • Optimized CD19 CAR design B-ALL and B-NHL Obe-cel • Potential best-in-class efficacy and safety profile CD19 • Supported by state-of-the-art manufacturing B-cell mediated • Supported by mature FELIX clinical/CMC package autoimmune disease • Dual
Slide 14: Financial Results
Financial Results
Slide 15: Financial summary – Key Metrics
Financial summary – Key Metrics* USD ($’ 000) FY 2024 FY 2023 Variance Cash, cash equivalents and marketable securities 588,023 239,566 348,457 Total revenue, net 10,120 1,698 8,422 Cost and operating expenses: Cost of sales (11,387) - (11,387) Research and development expenses, net (138,436) (130,4
Slide 16: Upcoming news flow
Upcoming news flow
Slide 17: Autolus news flow
Autolus news flow Anticipated Milestone or Catalyst Anticipated Timing Initial data from SLE Phase 1 trial April 23 Company R&D event, New York April 23 Initial data from PY01 trial in pediatric ALL H2 2025 Notification from UK and EU regarding approval in ALL H2 2025 SLE Phase 1 trial presentation
Slide 18: Thank you
Thank you Autolus.com